Physician profile
Matthew Greer
NPI 1073045043
$1,809.01
in general payments reported to CMS, 2019-2025
34 companies · $952 in 2025
The $952 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2023: $182 · 2024: $424 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $228.55 | 2021-2023 | Agile Esophageal |
| Novartis Pharmaceuticals Corporation | $174.00 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $168.08 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Iba Proton Therapy, INC. | $134.00 | 2021 | |
| Histosonics, INC. | $96.57 | 2025 | |
| Lilly USA, LLC | $95.08 | 2025 | Verzenio |
| Daiichi Sankyo INC. | $82.18 | 2024-2025 | Enhertu, Vanflyta |
| Gt Medical Technologies, INC | $69.84 | 2023 | Gammatile |
| Glaxosmithkline, LLC. | $54.44 | 2024-2025 | Ojjaara |
| Incyte Corporation | $54.06 | 2024-2025 | Monjuvi, Pemazyre, Zynyz |
| Astrazeneca Pharmaceuticals Lp | $45.63 | 2024 | Imfinzi |
| Janssen Biotech, INC. | $42.44 | 2025 | Darzalex, Tecvayli, Rybrevant |
| Genentech USA, INC. | $38.42 | 2024-2025 | Phesgo, Ocrevus Zunovo |
| Bayer Healthcare Pharmaceuticals INC. | $34.84 | 2024-2025 | |
| Exelixis INC. | $33.60 | 2025 | Cabometyx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $31.80 | 2025 | Ayvakit |
| Coherus Oncology, INC. | $30.93 | 2025 | Loqtorzi |
| Genzyme Corporation | $29.85 | 2025 | |
| Rigel Pharmaceuticals, INC. | $29.15 | 2024 | Tavalisse, Rezlidhia |
| Novocure INC. | $26.71 | 2024 | Optune Lua (Novottf-200t) |
| Azurity Pharmaceuticals, INC. | $26.54 | 2025 | Danziten |
| Grifols USA, LLC | $25.80 | 2025 | Gamunex-C |
| Argenx US, INC. | $25.76 | 2024 | Vyvgart Hytrulo |
| Corcept Therapeutics | $24.97 | 2025 | Korlym |
| Iovance Biotherapeutics, INC. | $24.66 | 2025 | Amtagvi |
| Deciphera Pharmaceuticals INC. | $24.50 | 2025 | Qinlock, Romvimza |
| Sun Pharmaceutical Industries INC. | $23.88 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.80 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.77 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.62 | 2024 | Monoferric |
| Genmab U.S., INC. | $19.36 | 2024 | Tivdak |
| Pfizer INC. | $16.20 | 2025 | |
| Eisai INC. | $15.29 | 2025 | |
| Amgen INC. | $13.69 | 2024 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.